These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 31826071)
1. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C. Simili A; Mazzella G; Ravaioli F; Festi D; Bacchi-Reggiani ML; Porro A; Bazzoli F; Azzaroli F J Gastrointestin Liver Dis; 2019 Dec; 28(4):449-456. PubMed ID: 31826071 [TBL] [Abstract][Full Text] [Related]
2. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552 [TBL] [Abstract][Full Text] [Related]
3. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs. Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045 [TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y; Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062 [TBL] [Abstract][Full Text] [Related]
5. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Buivydiene A; Liakina V; Kashuba E; Norkuniene J; Jokubauskiene S; Gineikiene E; Valantinas J Medicina (Kaunas); 2018 Sep; 54(5):. PubMed ID: 30344298 [No Abstract] [Full Text] [Related]
6. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Attallah AM; Omran D; Marie MS; Abdelrazek M; Salama A; El Essawey R; Mobarak L; Maklad S; Omar A Br J Biomed Sci; 2018 Oct; 75(4):157-162. PubMed ID: 29914308 [TBL] [Abstract][Full Text] [Related]
7. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707 [TBL] [Abstract][Full Text] [Related]
8. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Eurich D; Boas-Knoop S; Bahra M; Neuhaus R; Somasundaram R; Neuhaus P; Neumann U; Seehofer D Transplantation; 2012 Mar; 93(6):644-9. PubMed ID: 22411462 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy. Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684 [TBL] [Abstract][Full Text] [Related]
10. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595 [TBL] [Abstract][Full Text] [Related]
11. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection. Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study. Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X Gene; 2022 Apr; 820():146235. PubMed ID: 35143946 [TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
14. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. Mücke VT; Thomas D; Mücke MM; Waidmann O; Zeuzem S; Sarrazin C; Pfeilschifter J; Vermehren J; Finkelmeier F; Grammatikos G Liver Int; 2019 Nov; 39(11):2174-2183. PubMed ID: 31207039 [TBL] [Abstract][Full Text] [Related]
15. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication. Ohta A; Ogawa E; Murata M; Matsumoto Y; Yamasaki S; Ikezaki H; Furusyo N J Med Virol; 2022 Oct; 94(10):5007-5014. PubMed ID: 35652276 [TBL] [Abstract][Full Text] [Related]
16. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. Miki D; Akita T; Kurisu A; Kawaoka T; Nakajima T; Hige S; Karino Y; Toyoda H; Kumada T; Tsuge M; Hiramatsu A; Imamura M; Aikata H; Hayes CN; Honda K; Seike M; Akuta N; Kobayashi M; Kumada H; Tanaka J; Chayama K J Gastroenterol; 2020 Dec; 55(12):1162-1170. PubMed ID: 33057914 [TBL] [Abstract][Full Text] [Related]
17. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
18. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M; Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361 [TBL] [Abstract][Full Text] [Related]
19. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. Raksayot M; Chuaypen N; Khlaiphuengsin A; Pinjaroen N; Treeprasertsuk S; Poovorawan Y; Tanaka Y; Tangkijvanich P J Gastroenterol; 2019 May; 54(5):427-436. PubMed ID: 30506232 [TBL] [Abstract][Full Text] [Related]
20. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]